Bausch + Lomb 3Q 2026: Revenue $1.38B, Net income $32M, EPS $0.09— 10-Q Summary
Bausch + Lomb reported Q3 2026 revenue of $1.38B, up 7.3% YoY, and net income of $32M, reversing a $28M loss from the prior year. EPS was $0.09, compared to a loss of $0.08. Pharmaceuticals revenue grew 11%, led by MIEBO®. The FDA is reviewing Lumify NXTTM, with approval expected in 2027.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data that could influence short‑term price action and sector sentiment.
Market read
First disclosure of Q3 results; modest earnings beat may prompt short‑term buying.
What to watch
Pending FDA approvals and the warning letter for the Tampa facility could offset earnings upside.
Background
Bausch + Lomb filed its 10‑Q for Q3 2026, highlighting revenue growth, a profit swing, and ongoing FDA reviews.
Ticker impact
Q3 2026 earnings released showing revenue up 7.3% and a swing to $32M profit.
potential modest upside as market prices in the profit swing
The company posted a profit after a loss year‑over‑year, indicating improved performance that could attract buying.
Market effects
Eye‑care and ophthalmic devices sector may see broader optimism from BLCO's rebound.
U.S. healthcare stocks could experience slight positive pressure.
Limited to U.S. listed healthcare equities.
Counterpoint
The profit swing may be temporary; underlying margins remain thin.
Key entities
- companyBausch + Lomb
U.S. ophthalmic health products manufacturer (ticker BLCO).
